



Data on VIVUS' Qnexa(R) To Be Presented at the National Medical Association Annual Assembly

MOUNTAIN VIEW, Calif., July 29, 2010 /PRNewswire via COMTEX News Network/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that data on Qnexa(R), an investigational drug candidate, will be presented at the 2010 National Medical Association Annual Convention & Scientific Assembly (NMA), being held from July 31 - August 4, 2010 in Orlando, Florida. Dr. A. Julian Munoz, from The Division of Metabolism, Endocrinology & Diabetes at the University of Michigan, will deliver an oral presentation on Saturday, July 31st entitled: "Weight Loss With Low-Dose, Controlled-Release Phentermine/Topiramate in African American Subjects vs. Non-African American Subjects: Pooled 1-Year Data from Two Phase 3 Trials." The data will also be presented in a poster presentation session on Tuesday, August 3rd.

Following are details about the upcoming presentation:

2010 National Medical Association Annual Convention & Scientific Assembly (NMA) in Orlando, Florida

Date and Time: Saturday, July 31, 2010, 8:00-2:00 PM (actual time to be decided morning of - sorry)

Location: Gaylord Palms Hotel, Orlando, Florida

Session: Oral Presentation Session

Presentation Title: Weight Loss With Low-Dose, Controlled-Release Phentermine/Topiramate in African American Subjects vs Non-African American Subjects: Pooled 1-Year Data from Two Phase 3 Trials.

Chairs: Henry R. Black, MD and George L. Bakris, MD

Presenter: A. Julian Munoz, MD, MSPH

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's lead product in clinical development, Qnexa(R), has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor for the treatment of erectile dysfunction. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2009 and periodic reports filed with the Securities and Exchange Commission.

CONTACT :

VIVUS, Inc.
Timothy E. Morris
Chief Financial Officer
650-934-5200

Investor Relations: The Trout Group
Brian Korb
646-378-2923

Media Relations: Pure Communications,
Inc.
Dan Budwick
973-271-6085

SOURCE VIVUS, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved